These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8807733)

  • 1. An integrated view of the activities of defibrotide.
    Pescador R; Porta R; Ferro L
    Semin Thromb Hemost; 1996; 22 Suppl 1():71-5. PubMed ID: 8807733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defibrotide: properties and clinical use of an old/new drug.
    Pescador R; Capuzzi L; Mantovani M; Fulgenzi A; Ferrero ME
    Vascul Pharmacol; 2013; 59(1-2):1-10. PubMed ID: 23680861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
    Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption through the peritoneum of the macromolecular profibrinolytic drug defibrotide in the rabbit.
    Porta R; Calvani AB; Pescador R; Mantovani M; Prino G
    Semin Thromb Hemost; 1991 Oct; 17(4):404-6. PubMed ID: 1803509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.
    Palmer KJ; Goa KL
    Drugs; 1993 Feb; 45(2):259-94. PubMed ID: 7681375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.
    Ulutin ON; Cizmeci G; Balkuv-Ulutin S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):177-80. PubMed ID: 2459016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defibrotide as a possible anti-ischemic drug.
    Coccheri S; Nazzari M
    Semin Thromb Hemost; 1996; 22 Suppl 1():9-14. PubMed ID: 8807722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of defibrotide against myocardial ischemia and decline of beta-adrenoceptor function in the rabbit.
    Berti F; Rossoni G; Niada R; Omini C; Pretolani M; Mandelli C
    Haemostasis; 1986; 16 Suppl 1():13-7. PubMed ID: 3011616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defibrotide reduces monocyte PAI-2 and procoagulant activity.
    Abbate R; Gori AM; Martini F; Attanasio M; Comeglio P; Giusti B; Zarone N; Francalanci I; Prisco D; Gensini GF
    Semin Thromb Hemost; 1995; 21(2):245-50. PubMed ID: 7660147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
    Echart CL; Graziadio B; Somaini S; Ferro LI; Richardson PG; Fareed J; Iacobelli M
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial mechanisms of action of a prostacyclin enhancing agent in splanchnic artery occlusion shock.
    Aoki N; Siegfried M; Tsao P; Lento P; Lefer AM
    Res Commun Chem Pathol Pharmacol; 1988 Jun; 60(3):275-89. PubMed ID: 3175328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defibrotide is antithrombotic and thrombolytic against rabbit venous thrombosis.
    Niada R; Pescador R; Porta R; Mantovani M; Prino G
    Haemostasis; 1986; 16 Suppl 1():3-8. PubMed ID: 3519381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel beneficial mechanisms of defibrotide, a prostacyclin enhancing agent in splanchnic artery occlusion and reperfusion in rats.
    Ma XL; Porta R; Pescador R; Lefer AM
    Methods Find Exp Clin Pharmacol; 1991 Dec; 13(10):667-74. PubMed ID: 1663194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology and clinical pharmacology of defibrotide: a new profibrinolytic, antithrombotic and anti-platelet substance.
    Ulutin ON; Balkuv-Ulutin S; Ugur MS; Ulutin T; Ozsoy Y; Cizmeci G
    Adv Exp Med Biol; 1990; 281():429-38. PubMed ID: 2102624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel insight into the mechanism of the antithrombotic action of defibrotide.
    Tettamanti R; Bianchi G; Vitte PA; Kato G; Porta R; Thiemermann C; Pescador R; Mantovani M
    Life Sci; 1992; 51(19):1545-55. PubMed ID: 1331634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of superficial vein thrombosis treated with defibrotide: comparison with low dose subcutaneous heparin.
    Belcaro G
    Int J Tissue React; 1990; 12(5):319-24. PubMed ID: 2098372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits.
    Paul W; Gresele P; Momi S; Bianchi G; Page CP
    Br J Pharmacol; 1993 Dec; 110(4):1565-71. PubMed ID: 8306102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the use of defibrotide.
    Guglielmelli T; Bringhen S; Palumbo A
    Expert Opin Biol Ther; 2012 Mar; 12(3):353-61. PubMed ID: 22283742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defibrotide therapy for thrombophlebitis--controlled clinical trial.
    Di Perri T; Vittoria A; Messa GL; Cappelli R
    Haemostasis; 1986; 16 Suppl 1():42-7. PubMed ID: 3754835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostacyclin release from endothelial cells, induced by defibrotide treatment, favours the function of grafted rat hearts and kidneys.
    Ferrero ME; Marni A; Salari PC; Spaggiari PG; Gaja G
    Int J Tissue React; 1991; 13(4):215-8. PubMed ID: 1821415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.